Latest News

SGLT2 inhibitors, GLP-1 RAs are effective, but costly in T2D

Publish date: July 10, 2019
Author(s):
Randy Dotinga
Katie Lennon

 

Recommended Reading

Type 2 diabetes remission: Reducing excess fat in the liver might be the key
Federal Practitioner
Linking Metabolic Health, Psychiatric Disease, and Oxytocin Levels
Federal Practitioner
Diabetes, hypertension remission more prevalent in adolescents than adults after gastric bypass
Federal Practitioner
How to reverse type 2 diabetes with a crash diet: the DiRECT approach
Federal Practitioner
Immunotherapy drug teplizumab may stall onset of type 1 diabetes
Federal Practitioner
Drastic weight loss prevents progression to type 2 diabetes, PREVIEW data suggest
Federal Practitioner
Breast cancer linked to 23% higher risk for new diabetes
Federal Practitioner
Do black patients with type 2 diabetes gain cardiac benefit from the SGLT2 and GLP-1 drugs?
Federal Practitioner
FDA issues warning on insulin pump cybersecurity weakness
Federal Practitioner
Metformin linked to lower dementia risk in black patients
Federal Practitioner